Alterity Therapeutics (ATHE) Share-based Compensation (IS) (2021 - 2025)

Alterity Therapeutics' Share-based Compensation (IS) history runs 5 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• In Q4 2025, Share-based Compensation (IS) rose 179.85% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $2.6 million (up 46.07% YoY), while the FY2024 annual figure was $581.2 billion, down 10.03% from the prior year.
• Share-based Compensation (IS) was $1.5 million for Q4 2025 at Alterity Therapeutics, up from $519710.4 in the prior quarter.
• In the past five years, Share-based Compensation (IS) ranged from a high of $1.5 million in Q4 2025 to a low of $203295.9 in Q4 2023.
• Historically, Share-based Compensation (IS) has averaged $645437.5 across 5 years, with a median of $519710.4 in 2024.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation (IS) sank 50.67% in 2023, then soared 179.85% in 2025.
• A 5-year view of Share-based Compensation (IS) shows it stood at $637659.6 in 2021, then tumbled by 35.37% to $412099.2 in 2022, then plunged by 50.67% to $203295.9 in 2023, then jumped by 155.64% to $519710.4 in 2024, then jumped by 179.85% to $1.5 million in 2025.
• The last three Share-based Compensation (IS) figures came in at $1.5 million (Q4 2025), $519710.4 (Q4 2024), and $203295.9 (Q4 2023), per Business Quant data.